Consensus Hangzhou Tigermed Consulting Co., Ltd

Equities

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2026-03-06			5-day change	1st Jan Change
57.37 ^CNY	+1.06%		-3.81%	+1.18%

Mar. 03	Frontage Unit Acquires Research Lab Firm from Tigermed Consulting Unit	MT
Feb. 13	Beijing Trimmune Biotech Co., Ltd. announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd	CI

Evolution of the Average Target: Hangzhou Tigermed Consulting Co., Ltd

Evolution of the Target Price: Hangzhou Tigermed Consulting Co., Ltd

Changes in Analyst Recommendations: Hangzhou Tigermed Consulting Co., Ltd

965e0ccd.57ZYORDkyyVf_yqr72w2ZAIQqa6AhRmKq-9evDBiSrA.3_09QCjXmnUwnEDuiQ5EM29P0OjuxnG7nt9s6G8mfuqf5hIOSbGjXGqTZw~05071ea947a7bc91a7a24c61adae044b

Analysts' recommendations: Hangzhou Tigermed Consulting Co., Ltd

24-08-29	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 47.29 Yuan From 50.75 Yuan, Keeps at Neutral	MT
24-08-29	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$28.56 From HK$30.65, Keeps at Neutral	MT
24-07-24	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 50.75 Yuan From 49.61 Yuan, Keeps at Neutral	MT
24-07-24	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$30.65 From HK$32.69, Keeps at Neutral	MT
24-03-05	Nomura Downgrades Hangzhou Tigermed Consulting to Neutral From Buy, Adjusts Price Target to 49.61 Yuan From 75.72 Yuan	MT
24-03-05	Nomura Downgrades Tigermed to Neutral From Buy, Adjusts Price Target to HK$32.69 From HK$57.77	MT
23-10-30	Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to HK$57.77 from HK$64.46, Keeps at Buy	MT
23-10-30	Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to 75.72 Yuan from 83.50 Yuan, Keeps at Buy	MT
23-07-24	Nomura Adjusts Tigermed to Buy From Neutral, Adjusts Price Target to 83.50 Yuan From 91.67 Yuan	MT
23-07-24	Nomura Upgrades Tigermed to Buy From Neutral, Adjusts Price Target to HK$64.46 From HK$79.47	MT
23-04-26	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$79.47 From HK$102.23, Keeps at Neutral	MT
23-04-26	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 91.67 Yuan From 118.38 Yuan, Keeps at Neutral	MT
23-02-16	Nomura Downgrades Tigermed to Neutral From Buy, Adjusts Price Target to HK$102.23 From HK$80.36	MT
23-02-16	Nomura Downgrades Tigermed to Neutral From Buy, Adjusts Price Target to 118.38 Yuan From 116.32 Yuan	MT
22-10-26	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 116.32 Yuan From 119.66 Yuan, Keeps at Buy	MT
22-10-26	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$80.36 From HK$105.58, Keeps at Buy	MT
22-08-30	UBS Adjusts Hangzhou Tigermed Consulting's Price Target to HK$126.22 From HK$138.82, Keeps at Buy	MT
22-08-30	UBS Adjusts Hangzhou Tigermed Consulting's Price Target to 147.28 Yuan From 154.78 Yuan, Keeps at Buy	MT
22-08-26	Nomura Adjusts Tigermed’s Price Target to 122.78 Yuan From 119.66 Yuan, Nomura Keeps at Buy	MT
22-08-26	Nomura Adjusts Tigermed’s Price Target to HK$105.58 From HK$108.33, Keeps at Buy	MT
22-08-02	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$108.33 From HK$115.13, Keeps at Buy	MT
22-08-02	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 122.78 Yuan From 125.87 Yuan, Keeps at Buy	MT
22-04-27	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$115.13 From HK$134.75, Keeps at Buy	MT
22-04-27	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 125.87 Yuan From 147.33 Yuan, Keeps at Buy	MT
22-03-14	Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$134.75 From HK$141.67, Keeps at Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	HANGZHOU TIGERMED CONSULTING CO., LTD					+19.38%
	LONZA GROUP AG					+31.41%
	BEONE MEDICINES AG					+39.85%
	CELLTRION, INC.					+19.95%
	IQVIA HOLDINGS INC.					+31.95%
	REVOLUTION MEDICINES, INC.					+29.82%
	ASCENDIS PHARMA A/S					+20.35%
	EUROFINS SCIENTIFIC SE					+9.21%
	MEDPACE HOLDINGS, INC.					+4.31%
	IONIS PHARMACEUTICALS, INC.					+24.93%
	Average					+23.12%
	Weighted average by Cap.					+26.52%